Yes, Cellectis is publicly traded, allowing individual and institutional investors to buy and sell its shares on major public stock exchanges. The company completed its initial public offering and lists its American Depositary Shares on the Nasdaq Global Market under the ticker symbol CLLS. Additionally, its ordinary shares are publicly listed and traded on Euronext growth markets in Europe under the ticker symbol ALCLS. Operating as a public entity requires the company to maintain transparent financial reporting, adhere to strict regulatory compliance standards, and disclose regular quarterly and annual financial statements to the market.